Urteste plans to start clinical trials of diagnostic test for pancreatic cancer
Urteste plans to start clinical trials in the EU for Panuri, its pancreatic cancer diagnostic test, in Q3 2025. The company will select a CRO (Contract Research Organization) in the coming weeks to conduct the trials, which will involve 550 patients across Poland and selected EU countries. Parallelly, Urteste is preparing for FDA-regulated trials in the U.S., with a final Q-submission meeting scheduled for mid-2025.
The European study aims to accelerate certification and commercialization, providing early results faster than the U.S. trial. Urteste currently develops 12 diagnostic prototypes for cancers responsible for 70% of global cancer-related deaths. Their enzyme-based urine test technology enables early cancer detection through color changes in urine samples.
